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potentially, predictive per-
formance are limited. To
overcome this limitation,
functional data analysis,
which describes the dose-
volume histogram as a
continuous curve, was
applied to modeling of se-
vere acute mucositis and
dysphagia and compared
with LR. Functional data
analysis models showed
slightly better predictive
performance and more robust
dose-response estimates than
LR.functional logistic regression models (functional partial least squareselogistic regres-
sion [FPLS-LR] and functional principal componentelogistic regression [FPC-LR])
along with clinical data. This approach was compared with penalized logistic regres-
sion (PLR) in terms of predictive performance and the significance of treatment covar-
iateeresponse associations, assessed using bootstrapping.
Results: The area under the receiver operating characteristic curve for the PLR, FPC-
LR, and FPLS-LR models was 0.65, 0.69, and 0.67, respectively, for mucositis
(internal validation) and 0.81, 0.83, and 0.83, respectively, for dysphagia (external
validation). The calibration slopes/intercepts for the PLR, FPC-LR, and FPLS-LR
models were 1.6/0.67, 0.45/0.47, and 0.40/0.49, respectively, for mucositis (internal
validation) and 2.5/0.96, 0.79/0.04, and 0.79/0.00, respectively, for dysphagia
(external validation). The bootstrapped odds ratios indicated significant associations
between RT dose and severe toxicity in the mucositis and dysphagia FDA models.
Cisplatin was significantly associated with severe dysphagia in the FDA models. None
of the covariates was significantly associated with severe toxicity in the PLR models.
Dose levels greater than approximately 1.0 Gy/fraction were most strongly associated
with severe acute mucositis and dysphagia in the FDA models.
Conclusions: FPLS and functional principal component analysis marginally improved
predictive performance compared with PLR and provided robust dose-response asso-
ciations. FDA is recommended for use in normal tissue complication probability
modeling.  2016 The Author(s). Published by Elsevier Inc. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Normal tissue complication probability (NTCP) modeling
uses radiation therapy (RT) dose data, often in combination
with clinical and biological data, to construct statistical
models of RT-induced toxicity. There are 2 distinct aims of
NTCP modeling: (1) accurate prediction of toxicity out-
comes for individual patients; and (2) estimates of associ-
ations between treatment covariates and toxicity. Accurate
prediction enables clinical decision support (1), treatment
plan comparison, treatment modality selection (2), and
personalized dose prescription (3). Robust estimates of
associations between covariates and toxicity can inform the
design of RT planning interventions aimed at reducing
toxicity.
A major weakness of many NTCP models is suboptimal
dimensionality reduction of the RT dose distribution
(reducing the number of variables used to describe the dose
distribution from all of the points on the 3-dimensional [3D]
dose grid to a small number of summary metrics). To input
dose data into statistical models, the 3D dose distribution
delivered to an organ at risk (OAR) is reduced to a single or
series of scalar metrics, for example, maximum dose or mean
dose, or multiple points sampled from the dose-volume his-
togram (DVH), such as the volume of an OAR receiving at
least x cGy (Vx). Ideally, information from each dose level
should be explicitly input into the model to prevent loss of
potentially important information. However, given the nature
of the dose deposition within the patient, adjacent dose levels
are very highly correlated (4). This is problematic for many
statistical modeling methods, such as the commonly used
logistic regression, which often exhibit biased regressioncoefficients with large standard errors in the presence of
collinearity (5). The structure of the correlations is often
consistent between patients because the volumes of an OAR
receiving adjacent dose levels are highly correlated for all
patients. Therefore, if the same or similar treatment tech-
niques are used, this does not necessarily prevent the models
from being able to accurately predict outcomes prospectively
for new patients. However, it does result in the regression
coefficients of the dosimetric covariates being biased and
having large standard errors. The apparent regression co-
efficients of the dosimetric covariates donot generalizewell to
new patients and, hence, should not be used to determine the
strength of associations between correlated dose metrics and
toxicity, as is commonly done (6).
A small number of studies have attempted to address this
issue through using principal component analysis (PCA) to
reduce the dimensionality of the DVH data (7-12). How-
ever, PCA has been shown to perform poorly when the
number of predictors (DVH points) is comparable to, or
larger than, the number of observations (patients), as is
often the case in NTCP modeling (9, 11). Functional data
analysis (FDA) is a statistical framework for analyzing
continuous curves rather than discrete measurements (13).
Treating an entire curve, for example, a DVH curve, as a
single entity removes the problem of correlation (14) and
explicitly retains the relationship between points on the
DVH curve, which standard, nonfunctional statistical
techniques do not capture. Data are represented as curves
through the use of basis functions. There are different types
of basis functions including a priori fixed bases, such as
splines or wavelets, and data-driven bases, for example,
functional principal component analysis (FPCA).
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dict binary outcomes. It is well suited to NTCP modeling
because of the continuous nature of DVH curves and the
binary nature of toxicity endpoints. Functional logistic
regression has recently been applied to NTCP modeling by
Benadjaoud et al (15), using FPCA (16) for dimensionality
reduction of the DVH data. However, FPCA (and
nonfunctional PCA) is unsupervised (it does not use
outcome data), which may be a limitation for NTCP
modeling. The FPCA components with the most variance in
the RT dose data may not be the ones that are most strongly
associated with the toxicity outcome of interest. Functional
partial least squares regression (FPLS) (17, 18) is a su-
pervised analogue of FPCA. It overcomes this limitation
through generating uncorrelated covariates (FPLS compo-
nents) in the linear space of the predictors, accounting for
the correlation between those predictors and outcome, in
this case toxicity. As partial least squares regression (and
FPLS) uses the outcome (toxicity) data in establishing the
components, it often outperforms PCA (and FPCA) in
prediction tasks (19). However, because of the inclusion of
outcome data, it is more susceptible to overfitting.
In this study we applied FPLS and FPCA to NTCP
modeling of severe acute mucositis and dysphagia. We
compared our novel application of FDAwith nonfunctional
penalized logistic regression (PLR) models. The aims of
this study were to (1) determine whether using FPLS or
FPCA to reduce the DVH data would improve predictive
performance compared with PLR; and (2) assess whether
FPLS or FPCA would lead to more robust estimates of
associations between DVH data and toxicity than PLR.Methods and Materials
Patient data
Data from 351 head and neck RT patients, enrolled in 1 of 6
different clinical trials (20-24) (International Standard
Randomised Controlled Trial Number 81772291), were
used to train and internally validate severe acute mucositis
and dysphagia NTCP models. Data from the same patients
were used for the modeling of both toxicities. This
dataset is described in Appendix A (available online at
www.redjournal.org) and the publication (25). Mucositis
and dysphagia were both consistently scored for all studies
using the Common Terminology Criteria for Adverse
Events version 2.0 instrument (26) or version 3.0 instru-
ment (27). The mucositis and dysphagia grading systems
are nearly equivalent in both versions. Both toxicities were
recorded, prospectively, for all patients prior to the start of
RT, weekly during RT, and at 1 to 4 and 8 weeks after RT
by head and neck cancer specialists trained in the use of the
scoring systems, using standard trial protocols. The toxicity
outcome was defined as the peak grade of toxicity,
dichotomized into grade 3 or worse (severe) and less than
grade 3 (non-severe). Grade 3 mucositis corresponds toconfluent mucositis and grade 3 dysphagia corresponds to
feeding-tube dependence for >24 hours. Patients with
baseline toxicity were excluded from the analysis. To
attempt to reduce bias at the expense of statistical power,
patients with any missing toxicity scores and a peak score
below 3 were excluded from the analysis. A detailed
justification for this approach is provided in Appendix B
(available online at www.redjournal.org). Of the 351 pa-
tients, 183 met the inclusion criteria for mucositis modeling
(severe mucositis incidence, 73%) and 179 met the inclu-
sion criteria for dysphagia modeling (severe dysphagia
incidence, 66%). Ninety head and neck RT patients treated
at Washington University School of Medicine in St Louis
with acute dysphagia data available were used as an
external validation cohort for the dysphagia models (severe
dysphagia incidence, 48%). In this cohort severe acute
dysphagia was defined as the requirement for percutaneous
endoscopic gastrostomy (PEG) tube insertion. It should be
noted that there was a slight difference in the scoring sys-
tems because of the data available. All centers involved in
treating patients included in this study used a reactive
approach to PEG insertion, that is, delaying insertion until
deemed clinically necessary.
Induction chemotherapy (yes or no), concurrent
chemotherapy regimen (cisplatin, carboplatin, 1 cycle of
cisplatin followed by 1 cycle of carboplatin, or none),
definitive versus postoperative RT, primary disease site
(grouped into oropharynx or oral cavity, nasopharynx or
nasal cavity, hypopharynx or larynx, parotid gland, and
unknown primary), age, and sex were also included as
covariates in the models. Concurrent chemotherapy was
administered in 2 cycles, on day 1 and day 29 of RT. A
comparison of the clinical covariate data in the training and
external validation datasets is provided in Appendix C
(available online at www.redjournal.org).RT dose data
The extended oral cavity (25) and pharyngeal mucosa
(described in Appendix D) were contoured by clinical on-
cologists and used as OARs in the mucositis and dysphagia
models, respectively. The physical dose distribution was
converted to the fractional dose distribution (physical dose
delivered in each fraction). This has been shown to be
appropriate for NTCP modeling of acute toxicity (28) as the
toxicities often develop before the total dose is adminis-
tered. The fractional dose distribution was described by the
normalized cumulative DVH. Preliminary work indicated
that corrections for different fractionation regimens based
on radiobiological models made negligible difference to the
results. This is because the fractionation regimens used
(Appendix A; available online at www.redjournal.org) were
similar. An alternative approach would be to use the cu-
mulative dose delivered up to the appearance of the toxicity
endpoint. However, treating clinicians’ subjective choice of
when to initiate a feeding-tube intervention would lead to
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time of intervention.
PLR model
For the nonfunctional model, the fractional DVH curves
were discretely sampled from 0.2 Gy to 2.6 Gy at 0.2 Gy
intervals. This sampling was chosen to encompass the
entire range of OAR doses with enough granularity to
capture the shapes of the DVHs. These DVH measurements
were input into a PLR model along with the clinical
covariates. Penalization was performed using the least ab-
solute shrinkage and selection operator (LASSO) (29).
LASSO reduces the magnitude of the regression co-
efficients, setting some to 0, to prevent overfitting. In the
context of correlated variables, it reduces the impact of
multicollinearity. The penalization strength was selected by
10-fold cross validation with the value producing the
highest average (over all of the cross validation folds) area
under the receiver operating characteristic curve (AUC) on
cross validation selected.
Functional data analysis
The fractional DVH curves (sampled from 0 Gy to 2.60 Gy
in 0.01-Gy intervals) were represented using penalized
FPCA (16, 30) and penalized FPLS (17, 31) basis func-
tions. FPCA is a dimensionality reduction technique that
represents the functional DVH data as orthonormal vector
components explaining the maximum variance between
patients in the DVH curves. The orthonormality constraint
removes the collinearity in the dose metrics used for sub-
sequent modeling and, hence, overcomes the limitations
associated with modeling collinear data. The functional
principal components represent the functional DVH data
(normalized volume as a function of dose, d for patient i),
Vi(d), as the sum of the eigenfunctions, xkðdÞ, weighted by
their coefficients, cik:
ViðdÞ  mðdÞZ
XN
kZ1
cikxkðdÞ ð1Þ
where m(d) is the mean V(d) and cik describes the score for
functional principal component k for the DVH of patient i
and is given by:
cikZ
Z
ðViðdÞ  mðdÞÞxkðdÞdd ð2Þ
The eigenfunctions, fxkðdÞgNkZ1, and their corresponding
eigenvalues (describing the amount of variance explained
by each eigenfunction), l1  l2  ., are determined by
eigendecomposition (factorization into eigenvalues and ei-
genvectors) of the covariance operator, S, where:X
ðd1;d2ÞZCov½Vðd1Þ;Vðd2ÞZE
ðVðd1Þ
 mðd1ÞÞðVðd2Þ  mðd2ÞÞT
 ð3Þ
in which d1 and d2 are two different dose levels and E is the
expected value. V(d) can be approximated by a small
number of principal components, kn, assuming that cikZ 0for k > kn, to achieve dimensionality reduction to a small
number of basis functions efficiently describing the varia-
tion between patients in the DVH data:
ViðdÞzmðdÞ þ
Xkn
kZ1
cikxkðdÞ ð4Þ
The eigenfunctions and their coefficients can then be
used in subsequent analyses. The FPCA components can be
used to estimate a toxicity outcome for patient i, yi, using a
functional linear model (30, 32):
yiZaþ
Z
bðdÞViðdÞddþ εi ð5Þ
where a is the intercept and εi is a centered random error.
When FPCA is used to describe the DVH data, b(d)
represents a “weighting function” describing the amount of
variation between patients at all dose levels on the DVH. It
can be approximated by kn eigenfunctions:
bðdÞZ
XN
kZ1
bkxkðdÞz
Xkn
kZ1
bkxkðdÞ ð6Þ
An estimate of the response, byi, can be made using the
following [with the derivation described in a previous
publication (30)]:
byiZaþ Z bðdÞViðdÞddzaþXkn
kZ1
bbkcik ð7Þ
where bbð1:knÞZcT:1ynl1 ;.; c
T
:kn
y
nlkn

ð8Þ
The model was fit to the data, placing penalization on
the curvature (second derivative) of the eigenfunctions, by:byiZxkxTk xk þ rxTkPxk1xTk yi ð9Þ
where r is the amount of penalization, P is the vector (0, 0,
1) that defines the penalty matrix such that the second de-
rivative (curvature) is penalized, and yi is the actual
outcome (toxicity) data for patient i. The choice of which
components to include (within the first 5 components) and
the magnitude of the roughness penalty, r, to apply
(selected from a set of values in the range from 0 to 1350)
to best estimate the toxicity outcomes were determined
using model selection criteria (MSC) (16) with the
Bayesian information criterion:
MSCðknÞZlog
"
1
n
Xn
iZ1

yi  byi2
#
þ logðnÞkn
n2
ð10Þ
where n is the number of patients. This penalizes the model
complexity to reduce overfitting. Models with different
values of r and kn were generated, and the combination of
values that minimized MSC was selected. The FPCA or
FPLS components included affect the smoothness of the
estimate of the b(d) function as the dominant mode of
variation tends to be smooth and roughness tends to in-
crease for subsequent modes of variation, in part because of
the orthogonality constraint.
FPLS is similar to FPCA but uses the response
(toxicity) data in constructing the FPLS components (17),
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N
kZ1, to establish orthogonal components that have
maximum covariance to the response. This is achieved
through maximizing the squared covariance between Vi(d)
and the response, yi, with the constraint that all compo-
nents are mutually orthogonal (31). This takes the place of
the eigendecomposition used for FPCA, described in
equation 3. The iterative algorithm used to compute the
FPLS components was described previously (33). When
FPLS is used for dimensionality reduction of the DVH
data, b(d) can be interpreted as a data-driven weighting
function for the importance of each dose level in causing
severe toxicity. It is important to consider that, as this is a
data-driven approach, the weighting function is an esti-
mate of the “true weighting function” over the range of
available data and is influenced by the structure (ie, dis-
tribution in dose-volume space) of the available data.
MSC was performed for the FPLS analysis in the same
manner as for FPCA. The FPCA and FPLS analyses were
bootstrapped with 2000 replicates to assess the uncer-
tainty in the shapes of the components.
The optimal FPCA and FPLS components (those pro-
ducing the lowest MSC) were used as basis functions as
input into functional logistic regression (34, 35) models
(functional principal componentelogistic regression [FPC-
LR] and functional partial least squareselogistic regression
[FPLS-LR]) along with the (nonfunctional) clinical cova-
riates. The functional logistic regression model describes
the probability of patient i having severe toxicity,
P(yi Z 1), and is given by:
ln
PðyiZ1Þ
PðyiZ0ÞZaþ
Xp
jZ1
bjZ
j þ
Z
bðdÞViðdÞddza
þ
Xp
jZ1
bjZ
j þ
Xkn
kZ1
bkcik ð11Þ
using the substitution for the functional linear model
described in equation 7, where a is the intercept and
fZjgpjZ1 are the nonfunctional covariates with regression
coefficients fbjgpjZ1. Maximum likelihood estimation of the
regression coefficients was performed using iteratively
reweighted least squares.
Model comparisons
The predictive performance and generalizability of the
models (addressing aim 1) were assessed in terms of
discrimination, calibration, and overall performance on
internal validation, as well as additionally for the dysphagia
models on external validation. The discriminative abilities
of the models were assessed using the AUC. Calibration
was evaluated by the slope and intercept of a logistic
regression model of the actual toxicity against the predicted
probability of severe toxicity (36, 37). Overall modelperformance was measured using the Brier score (BS) (38).
It is defined as:
BSZ
1
N
XN
tZ1
ðpt  ytÞ2 ð12Þ
where pt is the predicted probability, yt is the actual
outcome, and N is the number of predictions. The score
takes a value between 0 and 1, with lower values indicating
better performance.
For the internal validation, the performance metrics
were “corrected for optimism” using bootstrapping with
2000 replicates (39). The optimism-corrected performance
metrics, Mcorrected, were calculated by:
McorrectedZMapparent O ð13Þ
where Mapparent is the performance metric, for example,
AUC, calculated using all of the training data to both fit the
model and evaluate its performance, and the optimism, O,
is given by:
OZ
1
B
XB
bZ1

Mb; boot Mb; orig
	 ð14Þ
where B is the number of bootstrap replicates, Mb,boot is the
performance metric calculated using the bootstrap dataset b
to both fit and evaluate model performance, and Mb,orig is
the performance of the model fit using the bootstrap dataset
b evaluated on the original dataset. This provides an un-
biased estimate of internal validity, penalizing for over-
fitting. Model hyper-parameter tuning, such as the selection
of the amount of penalization for the PLR models and the
selection of components and penalization for the FDA
models, was performed for each bootstrap replicate. This
prevents any “data leakage” from the training data into the
internal validation data. The dysphagia models were used to
predict severe dysphagia probability for the external vali-
dation cohort. Those predictions were compared to the
actual PEG-dependence data for the cohort and the same
performance metrics calculated. The uncertainties of the
odds ratios (addressing aim 2) were assessed by calculating
bootstrapped 95% confidence intervals with 2000 repli-
cates. Statistical analysis was performed using the statisti-
cal computing R language version 3.2.4 (40) and the
fda.usc version 1.2.2 (41), glmnet version 2.0 (42), rms
version 4.5 (43) and val.prob.ci.2 (44) packages.
Results
For FPCA, the variances in the DVH data explained by the
first 5 FPCA components were 80.8%, 12.5%, 3.7%, 1.2%,
and 0.6% for mucositis and 70.8%, 14.5%, 5.6%, 4.4%, and
1.6% for dysphagia. For FPLS, the variances explained by
the first 5 FPLS components were 78.1%, 16.9%, 2.0%,
2.5%, and 0.6% for mucositis and 76.2%, 8.6%, 11.2%,
2.7%, and 1.3% for dysphagia. The model selection resul-
ted in the first 2 components being selected for the FPCA
and FPLS mucositis models and only the first component
being selected in both of the dysphagia FDA models.
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the mucositis FPCA model, 0 for the mucositis FPLS
model, and 1350 for both of the dysphagia FDA models.
Figure 1 shows the first FPCA and FPLS components for
the mucositis and dysphagia models. Bootstrapping the
FPCA and FPLS indicated that the shapes of the first FPCA
and FPLS components were very similar irrespective of the
random sample of patients selected. There was a general
trend that the FPCA and FPLS loadings increased with
increasing dose and sharply decreased to 0 at the maximum
dose. The FPCA components indicate that the variation
between patients in the volume of OAR irradiated to a
certain dose level increased with increasing dose level. The
same trend in the FPLS components indicates that higher
doses were more strongly associated with severe toxicity.
The decrease in the first FPCA and FPLS component
loadings at around 1.8 Gy (Fig. 1) for the dysphagia
training data is indicative of reduced variation in this region
of the DVHs between patients. This is likely to be because
most of the variation in the pharyngeal mucosa dose dis-
tribution between patients is related to the variation in
volume of overlap of the 2 different planning target vol-
umes (whose prescription dose levels correspond to the
positions of the 2 peaks in the FPCA and FPLS compo-
nents) with the pharyngeal mucosa.
For the PLR, FPC-LR, and FPLS-LR modeling,
oropharynx or oral cavity and no concurrent chemotherapy
were removed as covariates to prevent perfect collinearity
(correlation matrices are shown in Appendix E; available
online at www.redjournal.org). Odds ratios for other pri-
mary disease sites are thus relative to oropharynx or oral
cavity, and odds ratios for concurrent chemotherapy are
relative to no concurrent chemotherapy.
Regarding aim 1, the predictive performance of the 3
different mucositis and dysphagia models, as assessed by in-
ternal and external (for dysphagia) validation, is displayed in
Table 1. The mucositis models had modest (PLR and FPLS-
LR) or modest to good (FPC-LR) discriminative ability
[using the interpretation previously described (45)] on internal
validation. The discriminative abilities and overall perfor-
mances of the FPC-LRandFPLS-LRmodelsweremarginally
better than the PLRmodel. Calibrationwas relatively poor for
all of the models, with the FPC-LR and FPLS-LR models
overfitting the data (calibration slope<1) and the PLRmodel
underfitting the data (calibration slope >1). The underfitting
exhibited by the PLRmodels was likely due to over-shrinkage
of the regression coefficients by the LASSO penalization
caused by high multicollinearity. It should be noted that the
“correction for optimism”may have improved the calibration
of the PLR models, as they underfit the data.
The discrimination and calibration of the dysphagia
models were better than the mucositis models. All 3
dysphagia models had good discriminative ability on in-
ternal validation. The discriminative abilities of all 3
models increased on external validation, with the PLR
model showing good to excellent discrimination and the
FPC-LR and FPLS-LR models showing excellentdiscrimination. The overall performance of all of the
models was similar, both on internal validation and on
external validation. Calibration of all of the models on in-
ternal validation was modest, with the PLR model under-
fitting the data and the FDA models overfitting the data.
The FPC-LR and FPLS-LR models had substantially better
calibration than the PLR model on external validation. The
FPLS-LR model had marginally better calibration than the
FPC-LR model on external validation. A logistic calibra-
tion curve for the external validation of this model is shown
in Figure 2. The curve lies close to the identity line, indi-
cating good model calibration on external validation.
Concerning aim 2, the results of the bootstrapped
penalized and functional logistic regression odds ratios are
shown in Tables 2-4. The odds ratios for the covariates in
the PLR models were often set to 1 by the LASSO penal-
ization. In the mucositis and dysphagia PLR models, none
of the covariates was significantly associated with severe
toxicity. Conversely, there was a significant association
between the first FPLS component and severe toxicity in
the mucositis and dysphagia FPLS-LR models. The first
FPCA components were not significantly associated with
severe mucositis or dysphagia. Compared with the first
FPLS components, slightly less weight was given to the
higher doses (Fig. 1). It should be noted that the sign of the
FPCA component loadings is arbitrary, so the fact that the
odds ratios are <1 does not indicate that there is an inverse
correlation between RT dose and severe toxicity.
None of the clinical covariates was significantly asso-
ciated with toxicity in the mucositis models. Concurrent
cisplatin was significantly associated with severe acute
dysphagia in the FPC-LR and FPLS-LR models but not in
the PLR model. None of the clinical covariates was
significantly associated with severe toxicity in either of the
PLR models.Discussion
Our results show that FPC-LR and FPLS-LR produced
models with marginally better discrimination and overall
performance than PLR and superior calibration (aim 1).
They also show that FPCA and FPLS are appropriate
methods to provide robust estimates of dose-response as-
sociations, to inform RT planning, in the presence of highly
correlated DVH data (aim 2). We, therefore, encourage the
use of FDA methods in future NTCP modeling studies. We
suggest that our externally validated dysphagia FPLS-LR
model is suitable for clinical decision support. To our
knowledge, it represents the severe acute dysphagia model
with the best predictive performance to date. Previous
models of severe dysphagia during or shortly after RT that
measured discrimination had AUC values of 0.62 (46) and
0.74 (47). These studies did not perform external valida-
tion. The mucositis FPC-LR model had the best perfor-
mance on internal validation and should be externally
validated to determine its potential to aid clinical decision
0.09
0.06
0.03
0.00
Mucositis
FPCA
Mucositis
FPLS
Dysphagia
FPCA
Training
data
Dysphagia
FPCA
Validation
data
Dysphagia
FPLS
Training
data
Dysphagia
FPLS
Validation
data
Lo
ad
in
gs
Lo
ad
in
gs
Lo
ad
in
gs
Lo
ad
in
gs
Fractional dose (cGy) Fractional dose (cGy)
Fractional dose (cGy) Fractional dose (cGy)
Fractional dose (cGy) Fractional dose (cGy)
0.100
0.075
0.050
0.025
0 20 40 60 80 100 120 140 160 180 200 220 240 260 0 20 40 60 80 100 120 140 160 180 200 220 240 260
0.10
0.05
0.00
0.000
0.100
0.075
0.050
0.025
0 20 40 60 80 100 120 140 160 180 200 220 240 260 0 20 40 60 80 100 120 140 160 180 200 220 240 260
0.12
0.08
0.04
0.000.000
0.100
0.075
0.050
0.025
0 20 40 60 80 100 120 140 160 180 200 220 240 260 0 20 40 60 80 100 120 140 160 180 200 220 240 260
0.000
Lo
ad
in
gs
Lo
ad
in
gs
Fig. 1. First functional principal component (left column) and first functional partial least squares component (right column) for
mucositis training (top row), dysphagia training (middle row), and dysphagia external validation (bottom row) data bootstrapped
with 2000 replicates. Each line represents 1 bootstrap sample. The functional principal components show the variance in the patient
dose-volume histograms over the range of dose levels. The functional partial least squares components show the covariance between
the patient dose-volume histograms and toxicity outcomes over the range of dose levels. Note that the components for the validation
data set are shown for comparison with the training data and were not used in any of the model training or validation tasks.
Abbreviations: FPCAZ functional principal component analysis; FPLSZ functional partial least squares regression.
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Table 1 Predictive performance of mucositis and dysphagia models on internal validation (corrected for optimism by bootstrapping
with 2000 replicates) and external validation (for dysphagia models)
Model AUC Brier score Calibration slope Calibration intercept
Mucositis
PLR 0.65 0.21 1.6 0.67
FPC-LR 0.69 0.19 0.45 0.47
FPLS-LR 0.67 0.20 0.40 0.49
Dysphagia*
PLR 0.74/0.81 0.20/0.18 1.2/2.5 0.15/0.96
FPC-LR 0.76/0.83 0.19/0.18 0.59/0.79 0.21/0.04
FPLS-LR 0.75/0.83 0.20/0.18 0.56/0.79 0.22/0.00
Abbreviations: AUCZ area under receiver operating characteristic curve; FPC-LRZ functional principal componentelogistic regression; FPLS-LR
Z functional partial least squareselogistic regression; PLR Z penalized logistic regression.
* For the dysphagia models, the metrics of predictive performance are given as internal validation/external validation.
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jamiedean/fda-ntcp-models.
The shapes of the first FPLS components indicate that
both severe mucositis and dysphagia are most strongly
associated with the volume of the oral cavity or pharyngeal
mucosa receiving high and intermediate fractional doses
(greater than approximately 1.0 Gy). Therefore, RT plan-
ning interventions aiming to minimize the incidence of
severe acute mucositis and dysphagia should minimize the0.0 0.2 0.4
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Fig. 2. Logistic calibration curve of the functional partial leas
against actual toxicity outcome for the external validation data
probabilities, along with the actual outcome (where 0 indicates
displayed at the bottom of the figure.volumes of oral cavity and pharyngeal mucosa receiving
high and intermediate fractional doses, without compro-
mising other aspects of the plan, such as target coverage.
Although this is intuitively unsurprising, many RT planning
protocols, such as Radiation Therapy Oncology Group
(RTOG) 0912, RTOG 0920, and RTOG 1216, set planning
objectives based on OAR mean doses, which give equal
importance to low doses and high doses. This suboptimal
approach is likely taken because of the common use of1
0
0.6 0.8 1.0
 probability
Ideal
Logistic calibration
t squareselogistic regression dysphagia model predictions
. The relative frequency distribution of the raw predicted
non-severe dysphagia and 1 indicates severe dysphagia), is
Table 2 Odds ratios for penalized logistic regression models
Covariate
Mucositis model Dysphagia model
Odds ratio 95% CI Odds ratio 95% CI
Intercept 2.512 0.016-12.43 0.360 0.007-2.583
Male 1.000 1.000-2.554 1.000 1.000-1.945
Age 1.000 0.971-1.006 1.000 0.980-1.000
Definitive RT 1.000 0.110-1.000 1.000 0.544-1.000
Induction chemotherapy 1.000 0.410-1.166 1.000 1.000-2.089
Cisplatin 1.000 1.000-3.464 1.277 1.000-3.230
Carboplatin 1.000 0.361-4.015 1.000 1.000-4.278
Cis-carbo 1.000 0.136-1.769 1.000 0.989-2.930
Hypopharynx or larynx 1.000 1.000-14.71 1.000 1.000-2.203
Nasopharynx or nasal cavity 1.000 0.905-6.190 1.000 0.247-1.000
Unknown primary 1.000 0.022-1.000 1.000 0.945-1.210
Parotid 0.814 0.231-2.546 0.600 0.208-1.000
V020 1.000 1.000-1.119 1.000 1.000-1.031
V040 1.000 0.891-1.000 1.000 1.000-1.014
V060 1.000 1.000-1.032 1.000 1.000-1.003
V080 1.000 1.000-1.050 1.000 1.000-1.023
V100 1.000 0.934-1.000 1.000 1.000-1.029
V120 1.000 1.000-1.084 1.019 1.000-1.044
V140 1.000 0.917-1.000 1.000 1.000-1.019
V160 1.000 1.000-1.038 1.000 1.000-1.011
V180 1.002 1.000-1.085 1.000 0.997-1.009
V200 1.000 0.949-1.007 1.000 1.000-1.019
V220 1.000 1.000-1.098 1.008 1.000-1.031
V240 1.000 0.616-1.154 1.000 1.000-1.025
V260 1.000 1.000-1.000 1.000 1.000-1.000
Abbreviations: Cis-carbo Z 1 cycle of cisplatin followed by 1 cycle of carboplatin; RT Z radiation therapy; 95% CI Z 95% confidence interval
calculated by bootstrapping model fitting with 2000 replicates; Vx Z volume of organ receiving x cGy of radiation per fraction.
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aiming to elucidate dose-response relationships. The first
FPCA components, which are unsupervised, had similar
shapes to the first FPLS components, which are supervised,
suggesting that, for this dataset, the variation in severity of
toxicities is related to the variations in the DVHs. This
suggestion is further supported by the fact that the MSC for
FPCA selected the first FPCA component (the one
describing the most variation in the DVH data). This will
not necessarily be the case for all datasets. The variations in
the bootstrapped first FPLS components are slightly wider
than those of the first FPCA components (Fig. 1) because of
the presence of patients who did not follow the general
dose-response trend (ie, received lower doses but had se-
vere toxicity and vice versa). The substantial penalization
of the PLR odds ratios (many often being set to 1) shows
the limitations of using PLR models to infer associations
between correlated dosimetric covariates and toxicity, and
hence, we do not recommend its use in this context. Unlike
the FDA models, the PLR models were unable to identify
that high doses, greater than approximately 1.0 Gy/fraction,
had higher correlations with toxicity than low doses, as
would be intuitively expected.
The FDA models were also able to identify an associa-
tion between concurrent cisplatin and severe acute
dysphagia. The associations between cisplatin anddysphagia in the PLR model were not significant. This may
be due to the fact that concurrent chemotherapy was
correlated with the DVH metrics because of patients with
parotid gland primary tumors (who receive unilateral,
rather than bilateral, irradiation and, hence, lower pharyn-
geal mucosa doses) not receiving concurrent chemotherapy.
The number of patients receiving concurrent carboplatin or
a combination of cisplatin and carboplatin was low
(Appendix C; available online at www.redjournal.org),
leading to large uncertainties in the odds ratios for those
covariates. The FDA models featured large uncertainties for
the odds ratios of clinical covariates that were highly
correlated with other covariates or which applied to small
numbers of patients. It should be noted that the regression
coefficients of the clinical covariates were not penalized in
the FDA models.
There have been very few previous attempts to apply
FDA to NTCP modeling (15, 48, 49). These have used
either spline basis functions (48, 49) or FPCA (15). To our
knowledge, this study represents the first application of
FPLS to NTCP modeling. Many previous NTCP modeling
studies have not addressed the problem of the high un-
certainties of the model regression coefficients caused by
multicollinearity. Investigators who have recognized this
limitation have avoided the multicollinearity problem by
reducing the data describing heterogeneous dose
Table 3 Odds ratios for functional principal componentelogistic regression models
Covariate
Mucositis model Dysphagia model
Odds ratio 95% CI Odds ratio 95% CI
Intercept 12.89 1.035-1.734109* 1.616 0.142-77.46
Male 1.535 0.637-4.088 1.675 0.533-4.880
Age 0.991 0.951-1.029 0.988 0.943-1.027
Definitive RT 0.254 2.679109-1.773 0.997 0.080-7.541
Induction chemotherapy 0.487 0.070-1.960 1.100 0.210-7.670
Cisplatin 2.251 0.745-9.540 4.255 1.077-19.86*
Carboplatin 1.320 0.142-7.314107 4.429 0.685-8.332107
Cis-carbo 0.311 7.815109-2.531107 2.238 0.319-4.587107
Hypopharynx or larynx 4.371 0.512-143.9 1.723 0.193-1.881107
Nasopharynx or nasal cavity 2.370 0.308-1.096108 0.263 0.026-1.223
Unknown primary 0.136 3.042109-3.707 0.859 0.077-3.876106
Parotid 1.387 0.103-40.37 1.135 0.068-18.72
DVH FPC1 0.997 0.993-1.007 0.996 0.990-1.008
DVH FPC2 1.003 0.992-1.009 - 0.992-1.003
DVH FPC3 - 0.996-1.003 - 0.995-1.000
DVH FPC4 - 0.987-1.010 - 0.991-1.006
DVH FPC5 - 0.971-1.033 - 0.991-1.006
Abbreviations: Cis-carboZ 1 cycle of cisplatin followed by 1 cycle of carboplatin; DVH FPCxZ functional principal component x of dose-volume
histogram data; RT Z radiation therapy; 95% CI Z 95% confidence interval calculated by bootstrapping model fitting with 2000 replicates.
The sign of the functional principal component loadings is arbitrary, so the fact that the odds ratios are <1 does not indicate that there is an inverse
correlation between RT dose and severe toxicity.
* Statistically significant at a Z .05 level.
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maximum dose. However, this leads to suboptimal recom-
mendations for RT planning. For example, using mean dose
to optimize or assess RT plans gives equal weight to all
dose levels, whereas preferentially minimizing the volumeTable 4 Odds ratios for functional partial least squareselogistic reg
Covariate
Mucositis mode
Odds ratio 9
Intercept 12.90 0.961-2.4
Male 1.539 0.620-4.7
Age 0.991 0.947-1.0
Definitive RT 0.260 7.70710
Induction chemotherapy 0.484 0.064-2.4
Cisplatin 2.246 0.728-11
Carboplatin 1.315 0.110-1.0
Cis-carbo 0.313 8.66810
Hypopharynx or larynx 4.169 0.506-48
Nasopharynx or nasal cavity 2.336 0.350-1.4
Unknown primary 0.132 2.02010
Parotid 1.408 0.097-56
DVH FPLS1 1.004 1.002-1.0
DVH FPLS2 1.002 1.000-1.0
DVH FPLS3 - 1.000-1.1
DVH FPLS4 - 1.000-1.1
DVH FPLS5 - 1.000-1.0
Abbreviations: Cis-carbo Z 1 cycle of cisplatin followed by 1 cycle of carb
dose-volume histogram data; RTZ radiation therapy; 95% CIZ 95% confiden
* Statistically significant at a Z .05 level.of an OAR receiving high doses rather than low doses is, in
fact, likely to result in a lower toxicity incidence.
A limitation of our approach is that, as the technique is
an empirical dataedriven method, there are decreases in the
weighting function describing the relative importance of
each dose level with increasing dose, which does not have aression models
l Dysphagia model
5% CI Odds ratio 95% CI
241010 1.634 0.128-104.4
57 1.661 0.472-4.719
33 0.988 0.942-1.029
11-1.245 0.975 0.046-7.831
42 1.100 0.222-7.866
.33 4.235 1.083-20.88*
51108 4.393 0.580-8.424107
9-3.303107 2.245 0.324-4.247107
4.8 1.677 0.168-1.998107
57108 0.266 0.028-1.250
9-95.47 0.903 0.092-2.895106
.81 1.196 0.071-27.80
17* 1.005 1.001-1.016*
47 - 1.000-1.041
10 - 1.000-1.009
07 - 1.000-1.009
85 - 1.000-1.009
oplatin; DVH FPLSx Z functional partial least squares component x of
ce interval calculated by bootstrapping model fitting with 2000 replicates.
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when interpreting dose-response associations from these
components. This limitation could be overcome through
adopting a Bayesian approach whereby prior knowledge is
provided to the model dictating that, with increasing dose
level, the weighting function can only remain constant or
increase and not decrease. Mathematically, this would take
the form of a monotonically increasing prior function (48).
The slight difference in the dysphagia scoring systems
between the training and external validation cohorts may
have reduced the performances of the models on external
validation. However, the models performed at least as well
on external validation as internal validation. The relatively
small size of the external validation cohort should also be
considered a potential limitation.
In the future, FPCA or FPLS could be applied to the 3D
dose distribution (rather than the DVH) (15), either to a
single OAR or to the entire dose grid, encompassing mul-
tiple OARs. This would allow associations between spatial
aspects of the dose distribution and toxicity to be explored.
This would require accurate mapping of the 3D dose dis-
tributions onto a common reference.
Conclusions
FPC-LR and FPLS-LR models of severe acute mucositis
had marginally better discrimination than PLR on internal
validation. FDA models of dysphagia had marginally
improved discrimination and substantially superior cali-
bration compared with PLR on external validation, indi-
cating potential advantages for clinical decision support.
FPCA and FPLS enable robust estimates of dose-response
associations in the context of correlated dose data. This
permits understanding of the most beneficial OAR dose-
volume levels, Vx to reduce in RT planning. Minimizing
the volumes of the oral cavity and pharyngeal mucosa
receiving high and intermediate doses is expected to
reduce the incidence of severe acute mucositis and
dysphagia. We recommend that FDA methods be applied
to future NTCP modeling studies.
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